FIGURE 1.
Schematic representation of the integrated actions of pro‐resolving mediators. Left panel: Annexin A1 and lipoxin A4 are presented as exemplar ligands for formyl peptide receptor type 2 (FPR2), the pro‐resolving receptor. By activating this GPCR, the two agonists promote the integrated bioactions of resolution for a general reorganisation of the affected tissue or organ, to enable termination of inflammation and regain of whole or partial tissue/organ functionality. Right panel, another distinctive element of pro‐resolving therapeutics lies in the fact that their agonistic activity can amplify their effects (see interwoven network of actions of the left) and promote reprogramming of target cells. This would ensure (a) efficacy even when the agonist is no longer there, (b) a switch in cell phenotype or polarisation and (c) all‐in‐all longer‐lasting pharmacological efficacy. These characteristics require consideration for drug development with respect to pharmacokinetics, administration route and frequency